Avista Launches OTC Platform with Bag Balm Acquisition

Avista Healthcare Partners carved out a new consumer health platform Thursday, marking a deliberate bet that heritage over-the-counter brands can find fresh growth when stripped from larger corporate portfolios and given dedicated management.

The New York-based private equity firm launched Birchwell Consumer Health as a standalone entity and immediately funded its first acquisition: Bag Balm, the 130-year-old Vermont skincare brand that's spent generations as a barn staple before crossing over to mainstream consumers. Financial terms weren't disclosed, but the deal pulls Bag Balm away from family ownership for the first time in its history.

It's a move that reflects broader private equity interest in the $50 billion U.S. over-the-counter health market, where legacy brands often languish inside sprawling consumer goods conglomerates or family-run operations that lack the capital and infrastructure to compete in Amazon-era retail. Avista's thesis: buy these orphaned assets, modernize their go-to-market strategy, then roll up similar brands under one roof.

"We're not creating brands from scratch or betting on unproven products," said Avista Managing Director Christopher Kenney in the announcement. "We're finding products that already have loyal users and distribution, but haven't had the investment to evolve how they reach consumers." That's code for direct-to-consumer infrastructure, digital marketing playbooks, and e-commerce optimization — the table stakes that family-owned brands rarely build on their own.

Bag Balm isn't exactly a household name outside rural America, but that's part of the appeal. The lanolin-based ointment launched in 1899 to treat cracked udders on dairy cows. Farmers noticed it worked on their own chapped hands. Over decades, word-of-mouth pushed it into hardware stores, then drugstores, then — quietly — into skincare routines for consumers who've never set foot on a farm.

The brand's Vermont roots and agricultural heritage give it authenticity that modern CPG companies spend millions trying to manufacture. Its iconic green tin is recognizable. Its ingredient list is short. And unlike buzzy DTC skincare startups that burn cash chasing TikTok virality, Bag Balm already generates revenue — it's been profitable for over a century.

What it didn't have: a coherent digital presence, national retail expansion, or the kind of influencer-friendly packaging that drives impulse purchases on Instagram. That's where Avista sees the opportunity. Take a product with organic demand, clean up the brand architecture, and let performance marketing do the rest.

Birchwell Consumer Health will operate Bag Balm as a standalone brand within its portfolio, maintaining the Vermont manufacturing base while adding capabilities the family ownership couldn't afford: Amazon optimization, DTC subscription models, retail category management, and — eventually — international distribution. The playbook isn't novel, but it's proven. Private equity-backed platforms have successfully scaled everyone from Burt's Bees to Dr. Squatch using similar strategies.

Avista isn't the only firm making this bet. The over-the-counter consumer health category has seen steady deal flow over the past five years as branded pharma companies divest non-core assets and private equity looks for inflation-resistant categories with recurring purchase behavior.

KKR, Carlyle, and Advent have all built or backed OTC platforms in recent years. Prestige Consumer Healthcare, now publicly traded after multiple PE ownership cycles, built a $1 billion business rolling up brands like Monistat, Clear Eyes, and Dramamine. The category offers predictable cash flow, low customer acquisition costs relative to DTC-native brands, and distribution through channels — Walmart, CVS, Amazon — that aren't going anywhere.

Where Avista's angle differs slightly: Birchwell is explicitly targeting heritage brands, not distressed pharma carve-outs. The firm wants products with nostalgic equity and multi-generational awareness, betting that consumers are more willing to pay premium prices for brands their grandparents used than for generic equivalents. That's a reasonable assumption — legacy brand equity has become a real moat as digital advertising costs spiral and new customer acquisition becomes prohibitively expensive.

The risk: heritage doesn't always translate to growth. Plenty of nostalgic brands have loyal but aging customer bases, and breaking into younger demographics requires more than slapping a vintage logo on Instagram ads. Birchwell will need to prove it can drive actual household penetration gains, not just milk existing consumers harder.

The U.S. OTC market hit roughly $50 billion in 2024, growing at a mid-single-digit CAGR that's expected to hold through 2028. It's not a rocket ship, but it's steady — the kind of defensive growth profile private equity likes when macro uncertainty is high. Pain relief, cough/cold, and dermatology categories dominate, representing about 60% of total sales.

Avista Healthcare Partners manages about $3.5 billion in committed capital and has spent two decades investing in healthcare services, pharma services, and medical products. It's not a consumer-first firm by pedigree, which makes the Birchwell launch notable. The firm is expanding its mandate into adjacent categories where healthcare intersects with consumer behavior — think Perrigo, not Procter & Gamble.

To lead Birchwell, Avista tapped Robert McKinnon as CEO, a former executive at Prestige Brands who spent years running P&L for OTC portfolios. That's a hire that signals seriousness. McKinnon knows how to optimize retail velocity, manage retailer relationships, and scale brands without blowing up margins. He's not a startup operator brought in to chase virality — he's a platform-builder brought in to do accretive roll-ups.

McKinnon's mandate is straightforward: acquire 3-5 additional brands over the next 24 months, integrate them under shared back-office infrastructure, and build enough scale to either IPO or sell to a strategic buyer. That timeline suggests Avista is running a 5-7 year hold period on Birchwell, standard for middle-market PE.

The CEO role also matters for deal sourcing. OTC brand acquisitions often hinge on relationships — family owners selling multi-generation businesses don't just take the highest bid. They want to know the brand will be respected, the employees taken care of, the Vermont factory kept open. Having an operator with industry credibility makes those conversations easier.

Avista's Kenney emphasized this in the release, noting the firm's focus on "preserving brand heritage while unlocking growth." That's the pitch to future sellers: we won't gut your brand for short-term cash, we'll invest in it. Whether that's true in practice depends entirely on how Birchwell executes over the next 18 months.

Birchwell didn't disclose its acquisition criteria explicitly, but based on Bag Balm's profile, the pattern is clear: heritage brands, $10-50 million in revenue, family or founder-owned, strong regional presence, underdeveloped digital channels. That describes hundreds of brands across categories like pain relief, oral care, foot care, first aid, and digestive health.

Potential targets include brands that used to be household names but have faded from national retail — products grandparents remember but millennials don't recognize. Think Absorbine Jr., Mercurochrome, or Noxzema, all of which have changed hands multiple times and could theoretically be repositioned with the right investment.

When private equity firms talk about "modernizing" consumer brands, they usually mean three things: building a DTC website, optimizing Amazon listings, and running paid social ads. That's table stakes, but it's also where most roll-ups fail. Slapping up a Shopify store doesn't create demand if the product isn't differentiated or the pricing doesn't make sense against Amazon's algorithmic discounting.

Where Birchwell could actually add value: subscription infrastructure. Bag Balm is a replenishment product — once someone starts using it, they tend to keep buying it. That's a perfect fit for auto-ship models that improve customer lifetime value and give the brand direct customer data instead of relying on retailer POS reports.

The other unlock: influencer partnerships that don't feel forced. Bag Balm already has organic TikTok mentions from users who discovered it through family members or stumbled on it in rural pharmacies. Amplifying that authenticity through micro-influencer seeding could drive awareness without the cringe factor of a 130-year-old brand trying to act like a Gen Z startup.

But the real test is Amazon. Over 50% of OTC purchases now start with an Amazon search, and winning the buy box requires constant optimization of pricing, reviews, advertising spend, and content. Brands that don't invest in Amazon-specific operations get buried. Birchwell will need to build a team that treats Amazon as a primary channel, not an afterthought.

The OTC roll-up model has a mixed track record. For every success like Prestige Brands, there are a dozen platforms that overpaid for brands, failed to integrate them, and eventually sold at a loss. The core risk: assuming that brand awareness equals growth potential.

Bag Balm has recognition in certain demographics, but that doesn't mean it has latent demand waiting to be unlocked. Rural consumers already know about it. Urban consumers haven't heard of it, and breaking through in competitive skincare aisles dominated by Korean beauty imports and Instagram-native brands is expensive. If customer acquisition costs spiral, the economics fall apart fast.

The other risk is integration complexity. Rolling up brands sounds simple until you're trying to harmonize supply chains, negotiate shared retail contracts, and consolidate warehousing without disrupting service levels. Birchwell will need operational excellence, not just deal-making prowess.

And then there's the family business wildcard. Bag Balm's sale marks the end of multi-generational ownership, which can create internal friction even after a deal closes. If key employees leave or manufacturing quality slips during the transition, the brand equity Avista paid for could erode quickly.

Avista didn't disclose the purchase price for Bag Balm, but comparable heritage brand transactions in the OTC space typically trade at 8-12x EBITDA. Assuming Bag Balm does $15-25 million in revenue at 20-25% EBITDA margins, that puts the entry valuation somewhere in the $25-50 million range — small enough to be a platform anchor, large enough to justify the infrastructure build.

For Birchwell to deliver returns, it needs to build a portfolio doing $150-200 million in revenue within 5 years, operating at 25-30% EBITDA margins. That's achievable through 4-5 add-on acquisitions if each brand contributes $20-40 million in revenue and the platform can extract 200-300 bps of margin improvement through shared services.

The exit multiple depends entirely on growth trajectory. If Birchwell can show consistent organic revenue growth in the 8-12% range while rolling up brands, it could command a 12-15x exit multiple from a strategic buyer like Prestige, Kenvue, or Haleon. That math works. But if growth stalls and the portfolio looks like a collection of declining heritage brands held together by cost cuts, the exit multiple compresses to 6-8x — and the fund returns look mediocre.

The IPO route is possible but unlikely unless Birchwell scales past $300 million in revenue with clear category leadership. Public markets aren't rewarding small-cap consumer companies right now, and the comp set — Prestige trades at roughly 10x EBITDA — isn't inspiring. A strategic sale makes more sense, especially if a larger OTC platform wants to acquire Birchwell's brand portfolio and operational infrastructure as a bolt-on.

The Birchwell launch isn't an isolated data point. It reflects a broader shift in how private equity approaches consumer goods: buy smaller, buy strategic, and focus on categories with structural tailwinds rather than chasing the next viral DTC unicorn.

The venture-backed DTC playbook — raise $50 million, burn it on Facebook ads, hope for an exit before the cash runs out — is largely dead. What's replacing it: disciplined roll-ups of profitable legacy brands that don't need to be invented, just repositioned. That's a more boring strategy, but it's also more capital-efficient and less dependent on consumer trend cycles.

For family-owned brands, the message is clear: if you're doing $10-50 million in revenue and haven't invested in digital infrastructure, someone will come calling with an acquisition offer. Whether you take it depends on how comfortable you are running a business in an era where Amazon controls distribution and TikTok drives discovery. For many multi-generation owners, that's not a world they want to navigate — and that's exactly what firms like Avista are counting on.

The next 12 months will show whether Birchwell can actually close follow-on deals and integrate them without breaking the operational model. If McKinnon announces two more acquisitions by mid-2026, the platform thesis is working. If not, Birchwell might end up as a single-brand hold that gets flipped quietly to a larger platform without the roll-up story ever materializing.

Either way, Bag Balm's new owners will learn what every private equity-backed consumer brand eventually learns: heritage is an asset, but execution is everything. And in a category where shelf space is finite and consumer attention is fragmented, even a 130-year-old brand can disappear if the fundamentals aren't there.